Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07556718 · ClinicalTrials.gov registry record · Phase 2
Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease
A Phase 2 study, sponsored by University of Michigan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT07556718 is a Phase 2 study that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 100 participants.
The verdict
NCT07556718, a Phase 2 study, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
Many individuals with Crohn's disease continue to experience abdominal pain, bloating, or bowel habit changes even when their inflammation is controlled. Amitriptyline is a medication commonly used at low doses to treat irritable bowel syndrome (IBS) and abdominal pain. This study will assess whether amitriptyline is safe and reduces those ongoing GI symptoms in adults with Crohn's disease in remission.
Interventions
- DRUG Placebo
- DRUG Amitriptyline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-06-03 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07556718
The ClinicalTrials.gov registry entry for NCT07556718 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07556718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07556718 about?
NCT07556718 is a clinical study titled "Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease". Many individuals with Crohn's disease continue to experience abdominal pain, bloating, or bowel habit changes even when their inflammation is controlled. Amitriptyline is a medication commonly used at low doses to treat irritable bowel syndrome (IBS) and abdominal pain. This study will assess whethe...
What is the current status of trial NCT07556718?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2026-06-03. Estimated completion is 2029-12.
What interventions are being tested in trial NCT07556718?
The interventions under investigation include: Placebo (DRUG), Amitriptyline (DRUG).
Who is sponsoring clinical trial NCT07556718?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.